Research Analysts Offer Predictions for Genelux Q1 Earnings

Genelux Co. (NASDAQ:GNLX - Free Report) - Analysts at Brookline Capital Management issued their Q1 2025 earnings per share estimates for Genelux in a research report issued on Tuesday, March 25th. Brookline Capital Management analyst K. Dolliver expects that the company will earn ($0.20) per share for the quarter. The consensus estimate for Genelux's current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Genelux's Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.16) EPS and Q4 2025 earnings at ($0.16) EPS.

Genelux (NASDAQ:GNLX - Get Free Report) last announced its earnings results on Friday, March 28th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.09).

Separately, HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Genelux in a research note on Monday. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $18.25.

Genelux Trading Down 5.5 %

NASDAQ:GNLX traded down $0.17 during trading hours on Thursday, hitting $2.91. The company's stock had a trading volume of 91,366 shares, compared to its average volume of 205,462. Genelux has a 52-week low of $1.60 and a 52-week high of $6.50. The stock has a market capitalization of $100.51 million, a P/E ratio of -3.06 and a beta of -1.41. The stock has a fifty day moving average of $4.06 and a 200-day moving average of $3.10.

Remove Ads

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC grew its stake in Genelux by 39.7% in the 3rd quarter. Geode Capital Management LLC now owns 316,160 shares of the company's stock worth $749,000 after acquiring an additional 89,854 shares during the period. Marshall Wace LLP increased its stake in Genelux by 51.4% in the fourth quarter. Marshall Wace LLP now owns 156,058 shares of the company's stock valued at $368,000 after purchasing an additional 52,958 shares during the last quarter. LPL Financial LLC boosted its stake in Genelux by 72.3% in the 4th quarter. LPL Financial LLC now owns 94,144 shares of the company's stock worth $222,000 after buying an additional 39,516 shares during the last quarter. LifeSteps Financial Inc. boosted its position in shares of Genelux by 11.1% in the fourth quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company's stock worth $205,000 after acquiring an additional 8,715 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in Genelux during the third quarter worth approximately $59,000. 37.33% of the stock is currently owned by institutional investors and hedge funds.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.